This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content

Erythropoiesis- Stimulating Agents: Continued Challenges

The interest of the public, elected representatives, and payers in the use of erythropoiesis-stimulating agents (ESAs) has grown in recent times. In May of this year, the New York Times published an article critical of physicians' use of ESAs, and attempts to link at least some of this use to rebates received by physicians from the manufacturers.¹ In addition, within the last several months, data published or released in preliminary form prompted the US Food and Drug Administration (FDA) to take several actions. In March, the FDA revised both the epoetin alfa and darbepoetin alfa product labels, with new "black . . . [Click for More]